e.m.m.a.

What e.m.m.a. does

e.m.m.a., operating commercially as Emma clinic and standing for European Market Maintenance Assessment, is a privately held French research-services firm headquartered in Fontenay-sous-Bois that develops and applies patient-reported outcome (PRO) questionnaires for chronic diseases. Its core product, the IDoL questionnaire suite, is built through a documented three-step methodology (conceptual/exploratory, development, and validation) executed by a multidisciplinary team that includes patient associations, specialist and primary-care physicians, nurses, and social workers, with a stated track record of more than 30 international peer-reviewed publications across dermatology, oncology, and other therapeutic areas.

The company monetizes this methodology by providing real-world data evaluation and market-maintenance assessment services to two primary customer groups: pharmaceutical and health-product manufacturers that need PRO evidence to support reimbursement and maintain product visibility, and healthcare professionals and health authorities that use the data for disease-management and resource-allocation decisions. Complementary offerings include Burden Questionnaires covering psychological, physical, social, and economic dimensions of disease impact, and the Pharm'Eco Epidémiologie training program on pre- and post-market authorization evaluation. Distribution is direct, project-based B2B/B2G engagement, with no disclosed platform, app, or self-service channel and no public pricing.

Operationally, e.m.m.a. is structured as a SASU (Société par actions simplifiée à associé unique) with €5,000 of stated capital, a single SIRET (814 004 669), and a single primary contact (Charles Taieb). The company has not disclosed external investors, funding rounds, headcount, or revenue, and operates with a regional European footprint centered on France. Its most prominent partnership is the OFICSel heart failure prevalence study managed jointly with the Groupe Interdisciplinaire en Cardiologie (GICC).

Name

e.m.m.a.

Legal name

SASU EMMA

Website

https://emma.clinic

Company type

Private

Operating status

Operating

Short description

e.m.m.a. (Emma clinic) is a French health-research firm that develops IDoL patient-reported outcome questionnaires for chronic diseases and provides real-world data and market-maintenance assessment services to pharmaceutical companies, healthcare professionals, and health authorities.

Ownership category

akta.pro rank

Product category

Healthcare Market Research & Patient-Reported Outcomes

NAICS

Research and Development in the Social Sciences and Humanities (541720), Scientific Research and Development Services (5417)

SIC

Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB)

akta.pro secondary industries

Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN), Market Access, Pricing & Reimbursement (Evidence Generation) FSP (HLAGAOAN), Value Dossier & Evidence Generation (AMCP/Global Value Dossier) (HLAIAKAC)

Keywords

• Patient-reported outcomes
• Clinical questionnaire design
• Real-world evidence studies
• Chronic disease assessment
• Market maintenance assessment

Headquarters

HQ city

Fontenay-sous-bois

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Distribution channels1 record

Marketing channels2 records

Core offering

Emma clinic designs and applies scientifically validated patient-reported outcome questionnaires (IDoL methodology) for chronic diseases, executes real-world evidence studies to support market access and reimbursement decisions for health products, and delivers the Pharm'Eco Epidémiologie training program. Its instruments capture impacts often overlooked in clinical consultations, including social exclusion, family burden, and economic consequences, and are co-developed with patient associations and multidisciplinary clinicians.

Product overview

EMMA Clinic operates as a European Market Maintenance Assessment company offering a portfolio of patient-centered assessment tools and services. The core offering consists of IDoL Questionnaires (patient questionnaires for chronic diseases following a 3-step methodology), Market Maintenance Assessment tools, and Burden Questionnaires that evaluate disease impact across psychological, physical, social, and economic dimensions. These are complemented by Pharm'Eco Epidémiologie Formation (training services) and the OFICSel research initiative on heart failure. The company has produced over 30 international scientific publications supporting its evidence-based approach.

Differentiator

Problem solved

Functional benefit

Brands

• European Market Maintenance Assessment: Full company name/brand identity as stated in company footer and business documentation.

Products and services

• IDoL Questionnaires
• Market Maintenance Assessment (Real-World Evidence Studies)
• Burden Questionnaires
• Pharm'Eco Epidémiologie Formation

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• GICC (Groupe Interdisciplinaire en Cardiologie)coreStrategic or Co-development PartnerEMMA manages the OFICSel project in partnership with GICC, focusing on heart failure in France. The study aims to develop precise recommendations to adapt dietary and therapeutic educational programs to individual patients, addressing the growing prevalence of heart failure due to population aging and improved management of etiological factors.

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Direct peers

• Clario (formerly ERT and CRF Health): Global leader in eCOA/ePRO technology and scientific data capture for clinical trials. Directly comparable to Emma as a provider of patient-facing outcome instruments, but operating at vastly larger scale with integrated electronic diary, telehealth, and clinical-trial platform offerings.
• Signant Health: Specialist eCOA/ePRO and patient-centric clinical technology provider serving pharma trial sponsors. Comparable to Emma in delivering patient-reported outcomes methodology, though Signant operates a full software platform versus Emma's questionnaire-development consulting model.
• Kayentis: French-headquartered eCOA/ePRO platform vendor focused on clinical trials and real-world studies. Closely comparable to Emma in therapeutic focus and origin, but with a proprietary software platform and broader global footprint.
• Mapi Research Trust (Mapi Trust): Non-profit custodian of the PROQOLID database of patient-reported outcome instruments. Directly comparable to Emma's IDoL questionnaire library as a PRO instrument steward, providing licensing, distribution, and copyright administration for established PRO measures.

Broad incumbents

• Medidata Solutions (Dassault Systèmes): Major clinical-trial technology platform with an integrated eCOA suite and RWE capabilities. Comparable to Emma on the patient-data-capture side but as part of a much broader life-sciences software portfolio serving global pharma trials.
• Evidera (PPD / Thermo Fisher Scientific): Global health economics, outcomes research, and real-world evidence consultancy supporting pharma market access and reimbursement. Directly comparable to Emma on the market access and evidence-generation value proposition, but operating as part of Thermo Fisher's clinical research services business.
• IQVIA: Largest global CRO with deep real-world evidence, HEOR, and patient-reported outcomes capabilities. Overlaps with Emma's pharma evidence-generation and market maintenance offerings as part of a much broader technology-enabled R&D and data services portfolio.
• Parexel International: Global CRO with dedicated real-world evidence and market access services for pharma. Comparable to Emma on patient-reported outcomes for reimbursement and post-marketing studies, embedded within full clinical-development offerings.
• ICON plc: Major global CRO with extensive real-world evidence, health economics, and patient-centered research services. Comparable to Emma as a buyer of PRO methodology for pharma evidence dossiers, though delivered through a global full-service operating model.

Regional players

• Observia: French health-data and patient-engagement company producing real-world evidence and patient-support programs across Europe. Comparable to Emma as a France-based patient-outcomes specialist but with a stronger digital health platform and broader European commercial reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/e-m-m-a-

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about e.m.m.a.